Sun revises sales forecasts but worries at two US facilities persist
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has raised its sales growth guidance for 2010-11 to 42% from about 35% previously though the revised estimates appear weighed down by uncertainties at its US arm, Caraco, among other factors.